{"disease":{"id":"resistant-cancer","name":"resistant cancer"},"drugs":{"marketed":[{"drug_id":"apalutamide","indication_name":"Castration-resistant prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Erleada","generic_name":"apalutamide","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"","quality_score":65,"revenue":"2600","mechanism":"Erleada blocks the androgen receptor, a protein that helps cancer cells grow."},{"drug_id":"talazoparib-with-enzalutamide","indication_name":"Metastatic castration-resistant prostate cancer (mCRPC) with BRCA1, BRCA2, or ATM gene mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Talazoparib with enzalutamide","generic_name":"talazoparib-with-enzalutamide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PARP enzymes and androgen receptor","drug_class":"PARP inhibitor and androgen receptor inhibitor","quality_score":10,"revenue":"2194","mechanism":""},{"drug_id":"darolutamide","indication_name":"Non-metastatic castration-resistant prostate cancer (nmCRPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nubeqa","generic_name":"darolutamide","company_name":"Bayer","drug_phase":"marketed","molecular_target":"androgen receptor (AR)","drug_class":"","quality_score":76,"revenue":"1600","mechanism":"Darolutamide inhibits androgen receptor activity, reducing prostate cancer cell growth and tumor size."},{"drug_id":"abiraterone-acetate","indication_name":"Metastatic castration-resistant prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zytiga","generic_name":"abiraterone-acetate","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Steroid 17-alpha-hydroxylase/17,20 lyase","drug_class":"Cytochrome P450 17A1 Inhibitor","quality_score":64,"revenue":"1500","mechanism":"Zytiga blocks the production of male hormones that fuel prostate cancer growth."},{"drug_id":"abiraterone","indication_name":"Metastatic castration-resistant prostate cancer (mCRPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abiraterone Acetate","generic_name":"abiraterone","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CYP17","drug_class":"Androgen biosynthesis inhibitor","quality_score":67,"revenue":"1500","mechanism":"Abiraterone is an androgen biosynthesis inhibitor that targets CYP17 to reduce androgen production in prostate cancer cells."},{"drug_id":"abiraterone","indication_name":"Chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abiraterone Acetate","generic_name":"abiraterone","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CYP17","drug_class":"Androgen biosynthesis inhibitor","quality_score":67,"revenue":"1500","mechanism":"Abiraterone is an androgen biosynthesis inhibitor that targets CYP17 to reduce androgen production in prostate cancer cells."},{"drug_id":"radium-223","indication_name":"Castration-Resistant Prostate Cancer, Bone Metastases","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Radium-223","generic_name":"radium-223","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Bone cells","drug_class":"Radiopharmaceutical","quality_score":50,"revenue":"400","mechanism":""},{"drug_id":"tetraxetan","indication_name":"metastatic castration-resistant prostate cancer (mCRPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pluvicto","generic_name":"TETRAXETAN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"","drug_class":"Radioligand Therapeutic Agent [EPC]","quality_score":10,"revenue":"386","mechanism":"Pluvicto works by binding to the PSMA protein on prostate cancer cells, delivering a radioactive payload to destroy the cancer cells."},{"drug_id":"lutetium-177lu-vipivotide-tetraxetan","indication_name":"PSMA-positive metastatic castration-resistant prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pluvicto","generic_name":"Lutetium (177Lu) vipivotide tetraxetan","company_name":"Aaa Usa Novartis","drug_phase":"marketed","molecular_target":"Prostate-specific antigen","drug_class":"Radioligand Therapeutic Agent [EPC]","quality_score":45,"revenue":"386","mechanism":"Pluvicto works by binding to prostate-specific antigen (PSMA) on cancer cells, delivering a radioactive payload that kills the cells."},{"drug_id":"tetraxetan","indication_name":"metastatic castration-resistant prostate cancer (mCRPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pluvicto","generic_name":"TETRAXETAN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"","drug_class":"Radioligand Therapeutic Agent [EPC]","quality_score":10,"revenue":"386","mechanism":"Pluvicto works by binding to the PSMA protein on prostate cancer cells, delivering a radioactive payload to destroy the cancer cells."},{"drug_id":"talzenna","indication_name":"HRR Gene-mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Talzenna","generic_name":"Talazoparib Tosylate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"PARP1 and PARP2 enzymes","drug_class":"PARP inhibitor","quality_score":75,"revenue":"182","mechanism":"PARP1/PARP2 inhibitor causing DNA damage, decreased proliferation, and apoptosis in BRCA-mutated cancers."},{"drug_id":"bevacizumab-maly","indication_name":"Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ALYMSYS","generic_name":"BEVACIZUMAB-MALY","company_name":"AMNEAL PHARMS LLC","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"sipuleucel-t","indication_name":"Metastatic castrate-resistant prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SIPULEUCEL-T","company_name":"","drug_phase":"marketed","molecular_target":"PAP","drug_class":"Autologous Cellular Immunotherapy [EPC]","quality_score":10,"revenue":null,"mechanism":"PROVENGE induces an immune response against PAP, an antigen found in most prostate cancers."},{"drug_id":"sipuleucel-t","indication_name":"Metastatic castrate-resistant prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SIPULEUCEL-T","company_name":"","drug_phase":"marketed","molecular_target":"PAP","drug_class":"Autologous Cellular Immunotherapy [EPC]","quality_score":10,"revenue":null,"mechanism":"PROVENGE induces an immune response against PAP, an antigen found in most prostate cancers."},{"drug_id":"chembl-chembl3183409","indication_name":"Non-metastatic castration-resistant prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"APALUTAMIDE","company_name":"","drug_phase":"marketed","molecular_target":"Androgen Receptor (AR)","drug_class":"","quality_score":48,"revenue":null,"mechanism":"Apalutamide binds to the androgen receptor, blocking its function and reducing tumor growth."},{"drug_id":"chembl-chembl254328","indication_name":"Metastatic castration-resistant prostate cancer (CRPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abiraterone Acetate","generic_name":"ABIRATERONE","company_name":"Janssen Biotech","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":42,"revenue":null,"mechanism":"Abiraterone Acetate blocks the production of androgens, which are hormones that prostate cancer cells need to grow."},{"drug_id":"palbociclib","indication_name":"Treatment of adult patients with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy, in combination with inavolisib and fulvestrant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib","generic_name":"palbociclib","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinases 4 and 6 (CDK4/6)","drug_class":"CDK4/6 inhibitor","quality_score":70,"revenue":null,"mechanism":"Palbociclib inhibits CDK4/6 to block G1/S cell cycle progression in ER-positive breast cancer."},{"drug_id":"zytiga","indication_name":"Metastatic castration-resistant prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zytiga","company_name":"Bukwang Pharmaceutical","drug_phase":"marketed","molecular_target":"Cytochrome P450 11B2, mitochondrial, Androgen receptor, Cytochrome P450 11B1, mitochondrial","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl4650215","indication_name":"endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Itovebi","generic_name":"INAVOLISIB","company_name":"Genentech Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":53,"revenue":null,"mechanism":"Itovebi works by blocking a specific enzyme called PIK3CA, which is involved in the growth and spread of cancer cells."},{"drug_id":"pluvicto","indication_name":"PSMA-positive metastatic castration-resistant prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pluvicto","company_name":"VA Office of Research and Development","drug_phase":"marketed","molecular_target":"Prostate-specific antigen","drug_class":"","quality_score":11,"revenue":null,"mechanism":null}],"pipeline":[{"drug_id":"olaparib-oral-product","indication_name":"Platinum-resistant/refractory high-grade serous ovarian cancer","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Olaparib Oral Product","company_name":"Duke University","drug_phase":"discontinued","molecular_target":"PARP-1 and PARP-2 (poly-ADP-ribose polymerase enzymes)","drug_class":"PARP inhibitor (DNA repair inhibitor)","quality_score":null,"revenue":null,"mechanism":"Olaparib inhibits poly-ADP-ribose polymerase (PARP) enzymes to impair DNA repair in cancer cells with BRCA mutations or homologous recombination deficiency."}],"offLabel":[],"totalMarketed":20,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT05561504","title":"Helicobacter Pylori Local Prevalence and Antibiotic Resistance","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Technical University of Munich","has_results":false},{"nct_id":"NCT06835218","title":"PROCARE - PROstate Cancer Real World Evidence Registry","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"UroTrials Company (GmbH)","has_results":false},{"nct_id":"NCT06783127","title":"Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Santa Chiara Hospital","has_results":false},{"nct_id":"NCT04801186","title":"Retrospective Study to Describe the Real-world Treatment Patterns and Associated Clinical Outcomes in Patients With Metastatic Castration-resistant Prostates Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":1920,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06204302","title":"An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States","phase":"","overall_status":"COMPLETED","enrollment_count":1800,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT02495974","title":"European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)","phase":"","overall_status":"COMPLETED","enrollment_count":1763,"lead_sponsor_name":"Astellas Pharma Europe Ltd.","has_results":false},{"nct_id":"NCT02066961","title":"A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":1533,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT07200830","title":"Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":1524,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT02141438","title":"Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":1472,"lead_sponsor_name":"Bayer","has_results":true},{"nct_id":"NCT04256993","title":"PRECISE, a Study to Gather More Information About Bone Fractures and Survival in Castration-resistant PRostate Cancer (CRPC) patiEnts Treated With Radium-223 in Routine Clinical practIce in SwedEn","phase":"","overall_status":"COMPLETED","enrollment_count":1434,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT02003924","title":"Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1401,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06013475","title":"An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings","phase":"","overall_status":"COMPLETED","enrollment_count":1375,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06136650","title":"A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1314,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT05176483","title":"Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":1314,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT01949337","title":"Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":1311,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":true},{"nct_id":"NCT02861573","title":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT00974311","title":"Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1199,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT02111577","title":"Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1182,"lead_sponsor_name":"SOTIO a.s.","has_results":true},{"nct_id":"NCT04516161","title":"EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)","phase":"","overall_status":"COMPLETED","enrollment_count":1180,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05701007","title":"Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland","phase":"","overall_status":"COMPLETED","enrollment_count":1083,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04587427","title":"A Study to Learn More About How Radium-223 is Being Used With Other Treatments in European Patients Who Have Not Received Radium-223 Before","phase":"","overall_status":"COMPLETED","enrollment_count":1067,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT02380274","title":"Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)","phase":"","overall_status":"COMPLETED","enrollment_count":1030,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT02669771","title":"Long-Term Specified Drug Use-Results Survey for Xtandi Capsule","phase":"","overall_status":"COMPLETED","enrollment_count":1018,"lead_sponsor_name":"Astellas Pharma Inc","has_results":false},{"nct_id":"NCT06764485","title":"A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":960,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT03170960","title":"Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":914,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT06629779","title":"A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":900,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT03732820","title":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":895,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT05362149","title":"An Observational Study, Called DEAR, to Learn More About Treatment With Darolutamide, Enzalutamide and Apalutamide in Men With Non-metastatic Castration-resistant Prostate Cancer in Real World Settings","phase":"","overall_status":"COMPLETED","enrollment_count":870,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT03927287","title":"Prognostic Role of Free Psa Ratio at Biochemical Recurrence After Radical Treatments for Prostate Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":822,"lead_sponsor_name":"Rabin Medical Center","has_results":false},{"nct_id":"NCT03748641","title":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":765,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":true},{"nct_id":"NCT07213674","title":"A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":750,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT02288247","title":"A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":688,"lead_sponsor_name":"Astellas Pharma Europe Ltd.","has_results":true},{"nct_id":"NCT06691984","title":"Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":675,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT04597125","title":"RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":654,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06551324","title":"A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT06334120","title":"An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05870748","title":"REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":600,"lead_sponsor_name":"Sutro Biopharma, Inc.","has_results":false},{"nct_id":"NCT05919264","title":"FOG-001 in Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":595,"lead_sponsor_name":"Parabilis Medicines, Inc.","has_results":false},{"nct_id":"NCT06378866","title":"Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":532,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03319628","title":"First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":523,"lead_sponsor_name":"Mersana Therapeutics","has_results":false},{"nct_id":"NCT06517719","title":"Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04833517","title":"Prospective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study)","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Universität des Saarlandes","has_results":false},{"nct_id":"NCT04769817","title":"ProsTIC Registry of Men Treated With PSMA Theranostics","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Peter MacCallum Cancer Centre, Australia","has_results":false},{"nct_id":"NCT04691804","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":496,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT06632977","title":"Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":474,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT05092360","title":"Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":456,"lead_sponsor_name":"Mural Oncology, Inc","has_results":true},{"nct_id":"NCT05489211","title":"Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":454,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03460977","title":"A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":453,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT01977651","title":"A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":424,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT03398655","title":"A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":408,"lead_sponsor_name":"Vascular Biogenics Ltd. operating as VBL Therapeutics","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}